AEterna Zentaris (AEZS) Momentum in a Row; Aerojet Rocketdyne (AJRD) Inks NASA Mega-Contract


Aeterna Zentaris Inc. (Nasdaq:AEZS) shares climbed more than 30% in pre-market trading Tuesday, representing the potential continuation in the upward direction by the company’s stock for second day in a row

Analysts at H.C. Wainwright raised their price target on AEterna Zentaris shares from $0.11.00 to $11.00, while maintaining a Buy rating. The specialty biopharmaceutical company reported the exercise of the final Series B Warrants subject to the previously disclosed November 1, 2015 agreement

AEZS stock finished the last trading session at $8.52, up $4.29 (or $101.42%), and 7,932,665 of its shares exchanged hands during the day, a large increase in activity versus its average volume (3m) of 763,732

AEterna Zentaris, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health, has 6.33M Shares Outstanding, Market Capitalization (intraday) of $53.91M and AEZS stock 52-week range is between $3.19 and $89.00 per share



Shares of Aerojet Rocketdyne Holdings, Inc. (NYSE:AJRD) soared over 14% before the opening bell on Tuesday as the company announced  a $1.16 billion contract awarded by NASA to restart production of the RS-25 engine for the agency’s most powerful rocket, and an approximately $200 million contract with aerospace giant Boeing Company (NYSE:BA) to build a service module propulsion system

Aerojet Rocketdyne recently reported third quarter sales of $440.5 million and a net loss of $(38.1) million, or $(0.62) per share for the period

Aerojet Rocketdyne Holdings, a world-recognized aerospace and defense leader, has 64.20M Shares Outstanding, Market Capitalization (intraday) of $1.04B and AJRD stock one-year range is $14.86 – $24.35 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at